Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.

Trial Details

NCT ID
NCT05623267
Phase
PHASE2 / PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sugemalimab
  • Placebo
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • 1、18 years or older. 2、Histologically or cytologically confirmed small cell lung cancer. 3、ECOG PS=0-1 at enrollment; 4、Limited-stage SCLC (Stage I…
  • 5、Inoperable SCLC, or the patient has contraindications to surgery, or the patient refuses surgery.
  • 6、Completion of 4 cycles of chemotherapy (etoposide + carboplatin/cisplatin) concurrent or sequential with radiotherapy during the first two cycles…
  • 7、After the completion of concurrent or sequential chemoradiotherapy, prophylactic intracranial irradiation (PCI) is allowed based on the common pr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →